Drug Trial Radar · NCT06143631
Prescription of Letrozole for Uterine Myoma
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Jul 24, 2024
Primary completion
Sep 11, 2028
Study completion Dec 11, 2028
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 21 years, up to 53 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.
Conditions
- Leiomyoma, Uterine
- Leiomyoma
- Fibroid
- Fibroid Uterus
Interventions
Letrozole 2.5mgDrug
Oral letrozole 2.5mg/day
PlaceboOther
Placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Uterine leiomyoma-related symptom severity over 12 weeks of treatmentTime frame: Baseline to 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
University of Mississippi Medical Center
Jackson, Mississippi · Recruiting
Duke University
Durham, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.